
Rezolute (RZLT) Stock Forecast & Price Target
Rezolute (RZLT) Analyst Ratings
Bulls say
Rezolute is a promising company, with a strong focus on developing therapies for rare and metabolic diseases such as congenital hyperinsulinism. Despite missing key endpoints in the phase 2b trial for their lead drug candidate, ersodetug, the company has implemented a streamlined phase 3 trial protocol for the drug in the tumor HI indication, which is currently enrolling patients. The company has sufficient cash to carry out this trial and potentially bring ersodetug to market for this patient population, while also exploring its potential in other indications.
Bears say
Rezolute is a biopharmaceutical company that is developing promising therapies for rare and metabolic diseases, with a focus on congenital hyperinsulinism and tumor-induced hyperinsulinism. However, there are significant risks associated with the company, including its financial standing and the need for additional capital, as well as potential competition and regulatory hurdles that could delay the approval of their products. As a financial analyst, the negative outlook on Rezolute's stock is based on the current lack of generated revenue, high capital needs, and the uncertainties and challenges that lie ahead for the company to successfully bring their therapies to market.
This aggregate rating is based on analysts' research of Rezolute and is not a guaranteed prediction by Public.com or investment advice.
Rezolute (RZLT) Analyst Forecast & Price Prediction
Start investing in Rezolute (RZLT)
Order type
Buy in
Order amount
Est. shares
0 shares